logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 7592337 B1

PDFFull Text
Date of Patent:
Sep. 22, 2009

Filed:

Mar. 07, 2003

Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5

Applicants:

Chixu Chen, San Diego, CA (US);

Nicholas D. P. Cosford, San Diego, CA (US);

Brian W. Eastman, San Diego, CA (US);

Dehua Huang, San Diego, CA (US);

Steve F. Poon, San Diego, CA (US);

Thomas S. Reger, San Diego, CA (US);

Jeffrey R. Roppe, Temecula, CA (US);

Nicholas D. Smith, San Diego, CA (US);

Inventors:

Chixu Chen, San Diego, CA (US);

Nicholas D. P. Cosford, San Diego, CA (US);

Brian W. Eastman, San Diego, CA (US);

Dehua Huang, San Diego, CA (US);

Steve F. Poon, San Diego, CA (US);

Thomas S. Reger, San Diego, CA (US);

Jeffrey R. Roppe, Temecula, CA (US);

Nicholas D. Smith, San Diego, CA (US);

Assignee:

Merck & Co., Inc., Rahway, NJ (US);

Attorneys:

J. Eric Thies

William Krovatin

Primary Examiner:

Rei-Tsang Shiao

Assistant Examiner:

Joseph R Kosack

Int. Cl.
CPC ...
A61K 31/535 (2006.01); A61K 31/4965 (2006.01); A61K 31/44 (2006.01); A61K 31/47 (2006.01); A61K 31/425 (2006.01); A61K 31/41 (2006.01); A61K 31/415 (2006.01); A61K 31/385 (2006.01); A61K 31/38 (2006.01); A61K 31/335 (2006.01); A61K 31/34 (2006.01); C07D 413/00 (2006.01); C07D 239/00 (2006.01); C07D 241/00 (2006.01); C07D 221/02 (2006.01); C07D 421/00 (2006.01); C07D 277/04 (2006.01);
U.S. Cl.
CPC ...
Abstract

Tetrazole compounds substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases.

Find Patent Forward Citations

Loading…